Melanogenesis-targeted anti-melanoma pro-drug development: Effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system

European Journal of Cancer Part A

Volumn 33, Issue 1, 1997, Pages 135-143

  Riley, P A ^b   Cooksey, C J ^b   Johnson, C I ^b   Land, E J ^b   Latter, A M ^b   Ramsden, C A ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

cytotoxicity; gluta thione; melanogenesis; melanoma; ortho quinones; pro drug; thiols; tyrosinase

Indexed keywords

GLUTATHIONE; MONOPHENOL MONOOXYGENASE; ORTHOQUINONE DERIVATIVE; PHENOL DERIVATIVE; PRODRUG; THIOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; LIVER CELL; MELANOGENESIS; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; DRUG SCREENING ASSAYS, ANTITUMOR; MELANOMA; MONOPHENOL MONOOXYGENASE; OXIDATION-REDUCTION; OXIMETRY; PHENOLS; PRODRUGS; QUINONES; RATS; SPECTROPHOTOMETRY; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0031020020     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00340-1     Document Type: Article

References (18)

1. 1. Riley PA. Hydroxyanisole depigmentation: in vivo studies. J Pathol 1969a, 97, 185-191.
2. 2. Riley PA. Hydroxyanisole depigmentation; in vitro studies. J Pathol 1969b, 97, 193-206.
3. 3. Riley PA, Sawyer B, Wolff MA. The melanocytotoxic effect of 4-hydroxyanisole. J Invest Derm 1975, 64, 86-89.
4. 4. Naish S, Cooksey CJ, Riley PA. Initial mushroom tyrosinase-catalysed oxidation product of 4-hydroxyanisole is 4-methoxyortho-benzoquinone. Pig Cell Res 1988a, 1, 379-381.
5. 5. Naish S, Holden JL, Cooksey CJ, Riley PA. The major primary cytotoxic product of 4-hydroxyanisole oxidation by mushroom tyrosinase is 4-methoxy ortho benzoquinone. Pig Cell Res 1988b, 1, 382-385.
6. 6. Morgan BDG, O'Neill T, Dewey DL, Galpine AR, Riley PA. Treatment of malignant melanoma by intravascular 4-hydroxyanisole. Clin Oncol 1981, 7, 227-234.
7. 7. Riley PA. Radicals and melanomas. Phil Trans R Soc Lond 1985, B311, 679-689.
8. 8. Riley PA. Melanogenesis: a realistic target for antimelanoma therapy? Eur J Cancer 1991, 27, 1172-1177.
9. 9. Schiller CD, Gescher A, Jheeta P. Mechanism of toxicity of the antimelanoma drug 4-hydroxyanisole in mouse hepatocytes. Eur J Cancer 1991, 27, 1017-1022.
10. 10. Rustin GJ, Stratford MR, Lamont A, et al Phase I study of intravenous 4-hydroxyanisole. Eur J Cancer 1992, 28A, 1362-1364.
11. 11. Belcher HJ, Nizarn M, O'Neill TJ. Intra-arterial 4-hydroxyanisole chemotherapy for locally recurrent malignant melanoma: a re-appraisal. Br J Plast Surg 1992, 45, 208-210.
12. 12. Stolze K, Nohl H. Formation of methemoglobin and phenoxyl radicals from p-hydroxyanisole and oxyhemoglobin. Free Radical Res Commun 1991, 11, 321-327.
13. 13. Stolze K, Nohl H. Methemoglobin formation from butylated hydroxyanisole and oxyhemoglobin. Comparison with butylated hydroxytoluene and p-hydroxyanisole. Free Radical Res Commun 1992, 16, 159-166.
14. 14. Naish-Byfield S, Cooksey CJ, Latter AM, Johnson CI, Riley PA. In vitro assessment of the structure-activity relationship of tyrosinase-dependent cytotoxicity of a series of substituted phenols. Melanoma Res 1991, 1, 273-287.
15. 15. Cooksey CJ, Land EJ, Riley PA, Sarna T, Truscott TG. On the interaction of anisy1-3,4-semiquinone with oxygen. Free Radical Res Commun 1987, 4, 131-138.
16. 16. Evans WC, Raper HS. The accumulation of 1-3:4-dihydroxyphenylalanine in the tyrosinase-tyrosine reaction. Biochem J 1937, 31, 2162-2170.
17. 17. Passi S, Nazzaro-Porro M. Molecular basis of substrate and inhibitory specificity of tyrosinase: phenolic compounds. Br J Derm 1981, 104, 659-665.
18. 18. Cooksey CJ, Land EJ, Ramsden CA, Riley PA, Tyrosinase-mediated cytotoxicity of 4-substituted phenols: quantitative structure-thiol-reactivity relationships of the derived o-quinones. Anti-Cancer Drug Design 1995, 10, 119-129.